Trastuzumab emtansine
- BNF:
- 8.5.5
- Status:
- Red
- Decision Date:
- August 2017
Comments
RED 1,2,3: NICE TA458 (replaces NICE TA371 - negative appraisal): for treating HER2-postive advanced breast cancer after treatment with trastuzumab and a taxane. (Decision date - August 2017)
RED1,2,3: NICE TA632 - for adjuvant treatment of HER2-positive early breast cancer. (Decision date - July 2020)
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
- 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
search again
